Biomarkers of good EULAR response to the B cell depletion therapy in all seropositive rheumatoid arthritis patients: Clues for the pathogenesis

PLoS ONE

Volumn 7, Issue 7, 2012, Pages

  Ferraccioli, Gianfranco ^a   Tolusso, Barbara ^a   Bobbio Pallavicini, Francesca ^b   Gremese, Elisa ^a   Ravagnani, Viviana ^c   Benucci, Maurizio ^d   Podestà, Edoardo ^e   Atzeni, Fabiola ^f   Mannocci, Alice ^g   Biasi, Domenico ^c   Manfredi, Mariangela ^d   Sarzi Puttini, Piercarlo ^f   Laganà, Bruno ^e   Montecucco, Carlomaurizio ^b  

^a CATHOLIC UNIVERSITY   (Italy)

^b UNIVERSITY OF PAVIA   (Italy)

^c UNIVERSITY OF VERONA   (Italy)

^d Ospedale di S Giovanni di Dio   (Italy)

^e SAPIENZA UNIVERSITY OF ROME   (Italy)

^f UNIVERSITY OF MILAN   (Italy)

^g SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; B CELL ACTIVATING FACTOR; BIOLOGICAL MARKER; CHLOROQUINE; CYCLIC CITRULLINATED PEPTIDE ANTIBODY; DISEASE MODIFYING ANTIRHEUMATIC DRUG; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; INTERLEUKIN 6; LEFLUNOMIDE; METHOTREXATE; MODIFIED CITRULLINATED VIMENTIN ANTIBODY; RHEUMATOID FACTOR; RITUXIMAB; SALAZOSULFAPYRIDINE; STEROID; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; UNCLASSIFIED DRUG;

ADULT; ARTICLE; ASSAY; B CELL DEPLETION THERAPY; DRUG RESPONSE; FEMALE; FOLLOW UP; HUMAN; IMMUNOTHERAPY; LOGISTIC REGRESSION ANALYSIS; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; OPEN STUDY; OUTCOME ASSESSMENT; PATHOGENESIS; REPEATED DRUG DOSE; RETROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; STEROID THERAPY; TREATMENT RESPONSE;

AGED; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTIRHEUMATIC AGENTS; AREA UNDER CURVE; ARTHRITIS, RHEUMATOID; AUTOANTIBODIES; B-CELL ACTIVATING FACTOR; B-LYMPHOCYTES; BIOLOGICAL MARKERS; FEMALE; HUMANS; INTERLEUKIN-6; LOGISTIC MODELS; LYMPHOCYTE DEPLETION; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; ROC CURVE; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 84864467675     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0040362     Document Type: Article

References (34)

1. Firestein GS, ((2003)) Evolving concepts of rheumatoid arthritis. Nature 423:: 356--361.
2. Silverman GJ, ((2006)) Therapeutic B cell depletion and regeneration in rheumatoid arthritis: emerging patterns and paradigms. Arthritis Rheum 54:: 2356--67.
3. O'Neill SK, Glant TT, Finnegan A, ((2007)) The role of B cells in animal models of rheumatoid arthritis. Front Biosci 12:: 1722--36.
4. Alivernini S, Laria A, Gremese E, Zoli A, Ferraccioli G, ((2009)) ACR70-disease activity score remission achievement from switches between all the available biological agents in rheumatoid arthritis: a systematic review of the literature. Arthritis Res Ther 11:: R163.
5. Hyrich KL, Lunt M, Dixon WG, Watson KD, Symmons DP, ((2008)) Effects of switching between anti-TNF therapies on HAQ response in patients who do not respond to their first anti-TNF drug. Rheumatology (Oxford) 47:: 1000--5.
6. Smolen JS, Weinblatt ME, ((2008)) When patients with rheumatoid arthritis fail tumour necrosis factor inhibitors: what is the next step? Ann Rheum Dis 67:: 1497--8.
7. Cohen SB, Emery P, Greenwald MW, Dougados M, Furie RA, et al. ((2006)) REFLEX Trial Group, Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy. Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis Rheum 54:: 2793--806.
8. Edwards JC, Cambridge G, Leandro MJ, ((2006)) B cell depletion therapy in rheumatic disease. Best Pract Res Clin Rheumatol 20:: 915--28.
9. Quartuccio L, Fabris M, Salvin S, Atzeni F, Saracco M, et al. ((2009)) Rheumatoid factor positivity rather than anti-CCP positivity, a lower disability and a lower number of anti-TNF agents failed are associated with response to rituximab in rheumatoid arthritis. Rheumatology (Oxford) 48:: 1557--9.
10. Chatzidionysiou K, Lie E, Nasonov E, Lukina G, Hetland ML, et al. ((2011)) Highest clinical effectiveness of rituximab in autoantibody-positive patients with rheumatoid arthritis and in those for whom no more than one previous TNF antagonist has failed: pooled data from 10 European registries. Annals Rheum.Dis 70:: 1575--80.
11. Arnett FC, Edworthy SM, Bloch DA, McShane DJ, Fries JF, et al. ((1988)) The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 31:: 315--24.
12. van Gestel AM, Prevoo ML, van't Hof MA, van Rijswijk MH, van de Putte LB, ((1996)) Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumatism Criteria. Arthritis Rheum 39:: 34--40.
13. Zweig MH, Campbell G, ((1993)) Receiver-Operating Characteristic (ROC) plots: A fundamental evaluation tool in Clin Med Clin Chem. 39:: 561--577.
14. Conaghan PG, Hensor EM, Keenan AM, Morgan AW, Emery P, et al. ((2010)) Persistently moderate DAS-28 is not benign: loss of function occurs in early RA despite step-up DMARD therapy. Rheumatology (Oxford) 49:: 1894--9.
15. Ferraccioli GF, Gremese E, Tomietto P, Favret G, Damato R, et al. ((2002)) Analysis of improvements, full responses, remission and toxicity in rheumatoid patients treated with step-up combination therapy (methotrexate, cyclosporin A, sulphasalazine) or monotherapy for three years. Rheumatology (Oxford) 41:: 892--8.
16. Pincus T, Ferraccioli G, Sokka T, Larsen A, Rau R, et al. ((2002)) Evidence from clinical trials and long-term observational studies that disease-modifying anti-rheumatic drugs slow radiographic progression in rheumatoid arthritis: updating a 1983 review. Rheumatology (Oxford) 41:: 1346--56.
17. Finckh A, Ciurea A, Brulhart L, Kyburz D, Möller B, et al. ((2007)) Physicians of the Swiss Clinical Quality Management Program for Rheumatoid Arthritis. B cell depletion may be more effective than switching to an alternative anti-tumor necrosis factor agent in rheumatoid arthritis patients with inadequate response to anti-tumor necrosis factor agents. Arthritis Rheum 56:: 1417--23.
18. Finckh A, Ciurea A, Brulhart L, Möller B, Walker UA, et al. ((2010)) Which subgroup of patients with rheumatoid arthritis benefits from switching to rituximab versus alternative anti-tumour necrosis factor (TNF) agents after previous failure of an anti-TNF agent? Ann Rheum Dis 69:: 387--93.
19. Emery P, Genovese MC, van Vollenhoven R, Sharp JT, Patra K, et al. ((2009)) Less radiographic progression with adalimumab plus methotrexate versus methotrexate monotherapy across the spectrum of clinical response in early rheumatoid arthritis. J Rheumatol 36:: 1429--41.
20. van Baarsen LG, Wijbrandts CA, Timmer TC, van der Pown Kraan TC, Tak PP, et al. ((2010)) Synovial tissue heterogeneity in rheumatoid arthritis in relation to disease activity and biomarkers in peripheral blood. Arthritis Rheum 62:: 1602--7.
21. Vos K, Thurlings RM, Wijbrandts CA, van Schaardenburg D, Gerlag DM, et al. ((2007)) Early effects of rituximab on the synovial cell infiltrate in patients with rheumatoid arthritis. Arthritis Rheum 56:: 772--8.
22. Teng YK, Levarht EW, Toes RE, Huizinga TW, van Laar JM, ((2009)) Residual inflammation after rituximab treatment is associated with sustained synovial plasma cell infiltration and enhanced B cell repopulation. Ann Rheum Dis 68:: 1011--6.
23. Edwards JC, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, et al. ((2004)) Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 350:: 2572--81.
24. Lai P, Su Z, Holveg CTJ, Silverman CJ, Schwartzman S, et al. ((2011)) Inflammation and autoantibody markers identify rheumatoid arthritis patients with enhanced clinical benefit following Rituximab treatment. Arthritis Rheum. 63,: 3681--91.
25. Sellam J, Hendel-Chavez H, Rouanet S, Abbed K, Combe B, et al. ((2011)) B-cell activation biomarkers as predictive factors of the response to rituximab in rheumatoid arthritis. Arthritis Rheum 63:: 933--8.
26. Fabris M, Salvin S, Saracco M, Pellerito R, Atzeni F, et al. ((2009)) BLyS promoter polymorphism and response to rituximab in rheumatoid arthritis (RA) patients positive or negative for the rheumatoid factor. Arthritis Rheum 60 (Suppl. 10):: 1678.
27. Edwards JC, Cambridge G, Abrahams VM, ((1999)) Do self-perpetuating B lymphocytes drive human autoimmune disease? Immunology 97:: 188--96.
28. Abraham VM, Cambridge G, Lydyard PM, Edwards JC, ((2000)) Induction of tumor necrosis factor alpha production by adhered human monocytes: a key role of Fcgamma receptor type IIIa in rheumatoid arthritis. Arthritis Rheum 43:: 608--616.
29. Cambridge G, Leandro MJ, Edwards JC, Ehrenstein MR, Salden M, et al. ((2003)) Serologic changes following B lymphocyte depletion therapy for rheumatoid arthritis. Arthritis Rheum 48:: 2146--54.
30. Cambridge G, Stohl W, Leandro MJ, Migone TS, Hilbert DM, et al. ((2006)) Circulating levels of B lymphocyte stimulator in patients with rheumatoid arthritis following rituximab treatment: relationship with B cell depletion, circulating antibodies and clinical relapse. Arthritis Rheum 54:: 723--32.
31. Bosello S, Youinou P, Daridon C, Tolusso B, Bendaoud B, et al. ((2008)) Concentrations of BAFF correlate with autoantibody levels, clinical disease activity, and response to treatment in early rheumatoid arthritis. J Rheumatol 35:: 1256--64.
32. Isaacs JD, Ferraccioli G, ((2011)) The need for personalised medicine for rheumatoid arthritis. Ann Rheum Dis 70:: 4--7.
33. Peluso G, Michelutti A, Bosello S, Gremese E, Tolusso B, et al. ((2011)) Clinical and ultrasonographic remission determines different chances of relapse in early and long standing RA. Ann Rheum Dis 70:: 172--75.
34. Isaacs JD, ((2010)) The changing face of rheumatoid arthritis: sustained remission for all? Nat Rev Immunol 10:: 605--11.